Parkinson’s Research Grant: Supporting Preclinical and Clinical Research

The Quarterly Research Grant Funding Programme is inviting applications for preclinical and clinical research aimed at slowing, stopping, or reversing Parkinson’s disease progression. The programme supports international applications from academic institutions and commercial organisations, offering up to £250,000 for preclinical research, while clinical trial funding is flexible.

About the Opportunity

The Quarterly Research Grant Funding Programme supports laboratory and clinical research focused on tackling the underlying progression of Parkinson’s disease.

The programme is specifically looking for research that can help:

• Prevent Parkinson’s

• Slow disease progression

• Stop progression

• Reverse progression

Priority is given to projects that show a clear route to clinical application within five years.

Funding Information

• Preclinical research: Up to £250,000 (GBP)

• Clinical trials: Flexible funding

• Clinical sub-studies: Funding available

• Infrastructure projects linked to trials: Funding available

What the Programme Supports

The fund supports both preclinical and clinical research.

Preclinical research may include:

• Laboratory studies on therapies targeting Parkinson’s progression

• Research with strong potential to move into clinical trials within 5 years

• Early-stage therapeutic development with translational promise

Clinical research may include:

• Clinical trials involving people with Parkinson’s

• Sub-studies linked to clinical trials

• Infrastructure projects that support clinical trial development

• Translational studies connected to patient-based research

Priority Focus

Strong preference is given to projects that:

• Target the underlying disease progression

• Have a clear translational pathway

• Could move toward clinical application within five years

• Show strong relevance to people living with Parkinson’s

Who Can Apply?

The programme accepts international applications from:

• Academic institutions

• Commercial organisations

This makes it suitable for both university-led research teams and private-sector or biotech-led therapeutic development projects.

Special Note for Commercial Applicants

Commercial organisations are eligible, but:

• Proposed costs must be clearly justified

• Costs should align with academic cost standards where possible

Applicants should also be aware that:

• All projects must comply with the grant contract terms and conditions

• Geopolitical, trade, economic, or sanctions-related restrictions may affect eligibility in some cases

Why This Grant Matters

This is a strong opportunity for researchers working on disease-modifying Parkinson’s therapies, especially projects that go beyond symptom management and aim to alter the course of the disease itself.

It is particularly valuable because it supports:

• Preclinical-to-clinical translation

• Clinical trials involving Parkinson’s patients

• Trial-enabling infrastructure

• International and cross-sector collaboration

What Makes a Strong Application?

Strong proposals are likely to show:

• A clear focus on slowing, stopping, or reversing Parkinson’s progression

• Strong scientific rationale

• A realistic path to clinical application within 5 years

• Robust preclinical or clinical methodology

• Clear patient relevance

• Feasible budget and timeline

• Translational potential, especially for therapeutic candidates

How to Apply

While the provided text does not include a deadline or application link, applicants should prepare:

• Detailed research proposal

• Scientific background and rationale

• Clear explanation of relevance to Parkinson’s progression

• Translational plan or pathway to clinical application

• Budget and justification

• Institutional or organisational details

• Regulatory/ethical readiness (for clinical work)

• Trial design details (if applying for clinical research)

Common Mistakes to Avoid

• Proposing research focused only on symptom management without addressing disease progression

• Failing to show a realistic 5-year clinical translation pathway

• Submitting weak budget justification, especially for commercial proposals

• Not clearly explaining how the project could support clinical trials

• Overlooking contract or compliance requirements

FAQs

What is the Quarterly Research Grant Funding Programme?

It is a research funding opportunity supporting preclinical and clinical Parkinson’s research aimed at slowing, stopping, or reversing disease progression.

How much funding is available?

• Up to £250,000 for preclinical research

• Flexible funding for clinical trials

• Support also available for clinical sub-studies and trial infrastructure

Who can apply?

The programme accepts international applications from academic institutions and commercial organisations.

What kinds of research are prioritised?

Projects that target the underlying progression of Parkinson’s and show a clear path to clinical use within five years are prioritised.

Are commercial organisations eligible?

Yes. Commercial applicants can apply, but costs should be well justified and aligned with academic standards where possible.

Conclusion

The Quarterly Research Grant Funding Programme is a valuable international funding opportunity for researchers and organisations developing disease-modifying approaches for Parkinson’s.

With up to £250,000 for preclinical studies and flexible support for clinical trials, it is especially well suited for projects with strong translational potential and a clear path toward helping people with Parkinson’s within the next five years.